Depulfavirine is under clinical development by Viriom and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase II drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Depulfavirine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Depulfavirine overview
Depulfavirine (VM-1500A) is under development for the prevention and treatment of human immunodeficiency virus (HIV) infection. It is a long acting injectable nanosuspension formulation of elsulfavirine administered through subcutaneous and intramuscular route. The drug candidate is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
See Also:
Viriom overview
Viriom operates as a clinical-stage drug development company that offers antivirals for HIV treatment and prevention. The company’s lead pipeline product includes Elpida, is a bioavailable prodrug. It also develops VM-1500A, a non-nucleoside HIV reverse transcriptase inhibitor. Viriom also provides development activities and early market access programs. The company serves hospital and over-the-counter market segments with drugs that provide treatment as well as pre-exposure and post-exposure prophylaxis. It operates in Japan and the US. Viriom is headquartered in San Diego, California, US.
For a complete picture of Depulfavirine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.